

Anti-TRP1/TYRP1 Antibody (Flanvotumab)

Introduction

Flanvotumab (IMC-20D7S) is a humanized monoclonal antibody targeting tyrosinase-related protein 1 (TYRP1), which is specifically expressed in melanocytes and melanoma cells. Flanvotumab functions through natural killer-mediated, antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has strong anti-tumor activity and good tolerability.

Product parameters

Alternative Names	IMC-20D7S, TA99, 20D7
Target Accession	P48995
Target	TRP1 / TYRP1
CAS number	1188277-05-5
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

